Fidelity Investments
VIGL

Fidelity Investments’s Vigil Neuroscience VIGL Stock Holding History

Fidelity Investments’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,086
Closed -$7.09K – 5826
2024
Q3 		$7.09K Sell
2,086
-810
-28% -$3K ﹤0.01% 4532
2024
Q2 		$11.6K Buy
2,896
+1,246
+76% +$4.26K ﹤0.01% 4278
2024
Q1 		$5.63K Sell
1,650
-139,184
-99% -$435K ﹤0.01% 4471
2023
Q4 		$476K Sell
140,834
-248
-0.2% -$1.28K ﹤0.01% 2698
2023
Q3 		$760K Buy
141,082
+682
+0.5% +$4.71K ﹤0.01% 2526
2023
Q2 		$1.32M Buy
140,400
+53,676
+62% +$507K ﹤0.01% 2422
2023
Q1 		$849K Buy
86,724
+74
+0.1% +$832 ﹤0.01% 2556
2022
Q4 		$1.08M Buy
86,650
+59,695
+221% +$733K ﹤0.01% 2517
2022
Q3 		$245K Buy
26,955
+26,915
+67,288% +$197K ﹤0.01% 2997
2022
Q2 		$0 Buy
+40
New +$158 ﹤0.01% 5516

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Fidelity Investments's VIGL Position: Q4 2024 in Review

Fidelity Investments sold out of Vigil Neuroscience (VIGL) in Q4 2024, closing a stake of 2,086 shares — an estimated $7.09K sold.

Fidelity Investments first reported a position in VIGL in Q2 2022 and held it in 10 quarters. The position peaked at $1.32M in Q2 2023. 51 funds tracked by Wall St. Rank hold VIGL as of Q4 2024.

  • Fidelity Investments reported no remaining Vigil Neuroscience position as of Q4 2024 after selling out during the quarter.
  • Fidelity Investments sold 2,086 Vigil Neuroscience shares in Q4 2024, an estimated $7.09K.
  • Fidelity Investments first reported a position in Vigil Neuroscience in Q2 2022 and held it in 10 quarters.
  • Fidelity Investments's Vigil Neuroscience position peaked at $1.32M in Q2 2023.
  • 51 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q4 2024.

Based on Fidelity Investments's 13F filing for Q4 2024, filed 13 Feb 2025.